Skip to the main content.

2 min read

Irvine Scientific Launches BalanCD CHO SLX A Culture Media Developed for the Selexis SURE CHO-M Cell Line

The New Media Improves SURE CHO-M Productivity

Geneva, Switzerland, June 6, 2012 – Selexis SA, a global life sciences company for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins, announced today the launch and availability of a chemically-defined, animal-component free media designed to greatly increase the productivity and viability of Selexis SURE CHO-M cell lines. This product, developed in collaboration with Irvine Scientific is designed exclusively for Selexis. The new formulation is called BalanCD™ CHO SLX A, improves cell viability, increases productivity during pilot and process development, and maintains consistency between runs. These and other benefits should facilitate scale-up in bioreactors.

Irvine Scientific, using its Rational Culture Media Design™ approach, worked with researchers at Selexis to develop a custom formulation that allows rapid optimization of processes where the SUREtechnology Platform™ is being evaluated or used.

"Our customers will be very satisfied with the outcome of this collaboration with Irvine Scientific, a company known for innovative, high production CHO formulations," said Igor Fisch, PhD, CEO of Selexis SA. “In combination with our SUREtechnology™ Platform, BalanCD™ CHO SLX A is an important new resource to further assist our customers in speeding drug development while reducing production costs and risks.”

"We are very pleased to be able to offer an optimized media for the Selexis SUREtechnology™ Platform, an industry standard for cell line development,” said Jessie Ni, PhD, CSO of Irvine Scientific. “BalanCD™ CHO SLX A represents an important expansion of Irvine Scientific’s portfolio of chemically-defined media. But more importantly provides a complete solution for customers that need to increase the speed with which they evaluate cell lines, the quality of proteins developed, and optimization of process development. The collaboration with Selexis can provide all these benefits to customers using CHO platforms for their protein therapeutics.”

To learn more about BalanCD™ CHO SLX A™, please contact Armelle Gaussin, PhD at armelle.gaussin@selexis.com, or TMrequest@irvinesci.com.

About Irvine Scientific
Irvine Scientific, a member of JX Holdings group, is a worldwide leader in the design, manufacture, and distribution of medical devices, including Industrial Cell Culture, Cytogenetic, Assisted Reproductive Technology (ART) and Specialty Media products. Irvine Scientific is a worldwide media provider that is regulated and adheres to both ISO and FDA regulations with dual manufacturing facilities in California, USA, and Tokyo, Japan. Irvine Scientific is a large scale producer of advanced quality cell culture media for the industrial bioprocess, medical, and diagnostic markets. The company’s extensive experience in the design of culture media, compliance with ISO and FDA regulations for class II / III medical devices, industrial scale manufacturing capacity, provides its customers with unique capabilities and support. Irvine Scientific delivers products worldwide to the biopharmaceutical industry, research and medical laboratory communities.

EXPLORING THE LIMITS OF CONVENTIONAL SMALL SCALE CHO FED BATCH FOR ACCELERATED ON-DEMAND MONOCLONAL ANTIBODY PRODUCTION

At KBI Biopharma, our PUREplatform™ is everything you need to make a protein. Catered to your needs, our service package contains plasmids, strains,...

Read More

Selexis and NexImmune Sign Service Agreement to Advance Multiple Immunotherapies Targeting Rare Cancers and Autoimmune Disorders

Agreement supports the development of molecules targeting acute myeloid leukemia, multiple myeloma, human papilloma virus (HPV) associated tumors,...

Read More

Accelerating the development of life-changing biological medicines in a new European state-of-the art facility

Biopharmaceutical companies are increasingly seeking service providers to help them reduce biologics manufacturing risks while increasing the speed...

Read More